Hereditary breast cancer: Risk assessment is the easy part

Breast Journal

Volumn 5, Issue 1, 1999, Pages 52-58

  Kelly, Patricia T ^a,b  

^a Catholic Healthcare West   (United States)

^b NONE   (United States)

Author keywords

Assessment; Breast cancer; Counseling; Genetic testing; Heredity; Hormone replacement therapy; Informed consent; Psychosocial; Risk

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CASE REPORT; FAMILY HISTORY; FEMALE; GENETIC SUSCEPTIBILITY; HEREDITY; HORMONE SUBSTITUTION; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; OVARY CANCER; PATIENT COUNSELING; RISK ASSESSMENT;

EID: 0032978723     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.1999.005001052.x     Document Type: Article

References (33)

1. Kelly PT. Breast cancer risk assessment and counseling: a clinician's guide. Breast J 1997;3:1-7.
2. Anderson DE, Badzioch MD. Risk of familial breast cancer. Cancer 1985;56:383-87.
3. Claus EB, Rich NJ, Thompson WD. Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol 1990;131:961-72.
4. Strong LC, Amos CI. Inherited susceptibility. In: Schottenfeld D, Fraumeni JF, eds. Cancer epidemiology and prevention. New York: Oxford University Press, 1996:559-83.
5. Easton DF, Ford D, Bishop DT, et al. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 1995;56:265-71.
6. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
7. Gayther SA, Warren W, Mazoyer S, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 1996;1:428-33.
8. Easton D. Breast cancer genes - what are the real risks? Nat Genet 1997;16:210-11.
9. Ford D, Easton DF, Bishop DT, et al. Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet 1994;343:692-95.
10. Narod SA. Hereditary breast carcinoma syndromes. Cancer 1997;80:537-42.
11. Tabar L, Duffy SW, Burhenne LW. New Swedish breast cancer detection results for women aged 40-49. Cancer 1993;72:1437-48.
12. Yanick R. Cancer in older persons: magnitude of the problem - How do we apply what we know? Cancer 1994;74: 1995-2101.
13. Piver MS, Jishi MF, Tsukada Y, et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. Cancer 1993;71:2751-55.
14. Ramus SJ. A breast/ovarian cancer patient. Nat Genet 1997;15:14-15.
15. Abeliovich D, Kaduri L, Lerer I, et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997;60:505-14.
16. Couch FJ, Deshano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997;336:1409-15.
17. Lilienfeld AM. Foundations of epidemiology. New York: Oxford University Press, 1976.
18. Colditz GA, Stampfer MJ, Willett WC, et al. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 1991;264:2648-53.
19. Stanford JL, Weiss NS, Voigt LF, et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995; 274:137-42.
20. Brinton LA, Hoover R, Fraumeni JF. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986;54:825-32.
21. Newcomb PA, Longnecker MP, Storer BE, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 1995;142:788-95.
22. Dupont WD, Page DL, Rogers LW, et al. Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk. Cancer 1989;63:948-57.
23. Palmer JR, Rosenberg L, Miller DR, et al. Breast cancer risk after estrogen replacement therapy: results from the Toronto breast cancer study. Am J Epidemiol 1991;134:1386-95.
24. Kaufman DW, Palmer JR, de Mouzon J, et al. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol 1991;134: 1375-85.
25. Weinstein AL, Mahoney MC, Nasca PC, et al. Oestrogen replacement therapy and breast cancer risk: a case-control study. Int J Epidemiol 1993;22:781-89.
26. Bergkvist L, Adami H-O, Persson I, et al. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen. Am J Epidemiol 1989;130:221-28.
27. Strickland DM, Gambrell RD, Butzin CA, et al. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol 1992;80:400-4.
28. Bonnier P, Romain S, Giacalone PL, et al. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995;85:11-17.
29. Grodstein F, Sampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336:1760-75.
30. Colditz GA, Hankinson SE, Hunter DJ. The use of estrogens and progestins and the risk of breast cancer in post-menopausal women. N Engl J Med 1995;332:1589-93.
31. Gambrell DR. Proposal to decrease the risk and improve the prognosis of breast cancer. Am J Obstet Gynecol 1984;150:119-28.
32. Criqui MH, Suarez L, Barrett-Connor E, et al. Postmenopausal estrogen use and mortality. Am J Epidemiol 1988; 128:606-14.
33. Hunt K, Vessey M, McPherson K, et al. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynecol 1987;94:620-35.